Ecolab (ECL) Q2 2024 earnings summary

Executive summary

• Q2 2024 sales rose 3% to $3.99–$4.0 billion, with organic sales up 4%–5%, led by Institutional & Specialty segment growth of 7%.

• Reported operating income increased 36% to $656.9 million, and adjusted diluted EPS rose 35% to $1.68; reported diluted EPS was $1.71, up 49%.

• Margin expansion continued, with Q2 operating margin up 360–390 bps to 16.5%–17.0%, and gross margin at 43.8%.

• Full-year 2024 adjusted EPS guidance raised to $6.50–$6.70, up 25%–29% year-over-year, despite FX and divestiture headwinds.

• The One Ecolab initiative was launched to drive $140 million in annualized savings by 2027 and support long-term growth.

Financial highlights

• Q2 reported sales: $3.99B (+3%); organic sales: +4%–5% year-over-year.

• Operating income: $656.9M (+36%); adjusted operating income: $678.5M (+32%).

• Gross margin expanded to 43.8% (+440 bps); adjusted gross margin up 420 bps.

• Cash from operations for the first six months: $1.26B, up from $771.6M a year ago.

• Free cash flow for Q2 was $414 million, up from $401 million a year ago.

Outlook and guidance

• Full-year 2024 adjusted EPS guidance raised to $6.50–$6.70, up 25%–29% year-over-year, including an $0.08 per share headwind from the surgical solutions divestiture.

• Q3 2024 adjusted EPS expected at $1.75–$1.85, up 14%–20% year-over-year.

• Long-term targets reaffirmed: 5%–7% organic sales growth, 20% operating margin, and 12%–15% EPS growth.

• The One Ecolab initiative targets $140 million in annual savings by 2027, with $175 million in restructuring costs expected.

• Management expects continued strong operating cash flow and sufficient liquidity for the next twelve months.